NeXXstep vaccine trials

Interested in joining a vaccine trial for Pneumoccocal disease?

The NeXXstep 12 study is inviting parents of babies aged up to 6 weeks who have not yet received the routine 2–3-month vaccinations to take part in a vaccine trial.

The study will follow 1200 children to evaluate the coverage and protection of an investigational pneumococcal vaccine compared to an approved pneumococcal vaccine.

Pneumococcal disease

Pneumococcal [noo-muh-KOK-ul] disease is caused by over 90 different types of pneumococcal bacteria. These bacteria can cause infections of the lungs (pneumonia), brain (meningitis), blood (bacteraemia) and ears (otitis media). In many cases, Pneumococcal disease is mild but can be serious especially in children younger than 2 years of age. 

The current vaccines provide protection against 10–13 types of pneumococcal germs. With the help of this vaccine research study, we are evaluating an investigational vaccine to find out if it can provide protection against 20 types of pneumococcal germs. The study will also look at the safety of the investigational vaccine when it is given with other routine childhood vaccinations.

What is a vaccine research study?

A vaccine research study brings people together to answer specific medical questions. Vaccine research studies are important because they help us understand whether a potential vaccine might provide different coverage and protection to the vaccines we use now. We can also find out what the benefits and risks are.

Does the investigational vaccine have any risks?

All vaccine research has some risk. Side effects with the approved pneumococcal vaccine are pain, tenderness, redness or swelling at the injection site, fever, irritability (fussiness), decreased appetite and sleepiness.

The side effects may be different from the investigational vaccine, however, the health and well-being of every child that takes part will be monitored. What we learn from the NeXXstep Study may benefit children in the future, by reducing the risk of pneumococcal disease.

Who can be involved?

The NeXXstep 12 study may be an option for healthy babies who:

  • are not premature
  • are up to 6 weeks of age
  • have not yet received the routine 2–3 month vaccinations

There are other requirements for participation in the NeXXstep 12 study. The study doctor will explain these to you.

What to do if you’re interested 

We understand that a vaccine research study is a big decision for you and your family. To find out more about the NeXXstep 12 study, email us at schn-nexxstep@health.nsw.gov.au or phone 0428 963 193.

Contacting us doesn’t mean your baby has to take part, and we would like to assure you that you can change your mind at any time. If you decide the NeXXstep 12 study is not right for your baby, they may still receive the routine vaccinations at the recommended ages. 

Complete the webform to register your interest and we'll be in touch.